Chromogenic Multiplex IHC Assay
May 26, 2021
Key topics discussed:
- Why choose chromogenic multiplex immunohistochemistry?
- Steps to follow to develop mIHC assays
- Our CD8/Granzyme B (GZMB)/FOXP3 assay and its clinical applications
- Challenges and future developments in the field
Download the resource
Why Choose CellCarta for your Histopathology Assays
We perform tissue analysis for biomarkers, clinical testing, and companion diagnostics using cutting-edge technologies and capabilities such as multiplex IHC and RareCyte. By supporting our team of in-house pathologists with AI we transform tissue biology into actionable data.
Contact us
Chromogenic Multiplex IHC Assay
May 26, 2021
Key topics discussed:
- Why choose chromogenic multiplex immunohistochemistry?
- Steps to follow to develop mIHC assays
- Our CD8/Granzyme B (GZMB)/FOXP3 assay and its clinical applications
- Challenges and future developments in the field
Download the resource
Why Choose CellCarta for your Histopathology Assays
We perform tissue analysis for biomarkers, clinical testing, and companion diagnostics using cutting-edge technologies and capabilities such as multiplex IHC and RareCyte. By supporting our team of in-house pathologists with AI we transform tissue biology into actionable data.
Contact us
Case Study: Identification and Monitoring of Problematic HCPs for Improved Process Development
October 21, 2019
This case study provides details on our methodology to ensure a reliable and comprehensive inventory of residual HCPs in your process intermediates and final drug substance.
GET A RELIABLE, COMPREHENSIVE INVENTORY OF RESIDUAL HCP IN YOUR PROCESS INTERMEDIATES AND FINAL DRUG SUBSTANCE
Why chose CellCarta for your Proteomic Assays
Mass spectrometry (MS) is the technology of choice for large-scale proteomic profiling and targeted quantitative biomarker analysis. CellCarta has led the way in the industrialization of MS platforms by applying them to the needs of the industry and refining MS workflows for specific clinical applications, all while applying GCLP principles and rigorous QA/QC.
Case Study: Identification and Monitoring of Problematic HCPs for Improved Process Development
October 21, 2019
This case study provides details on our methodology to ensure a reliable and comprehensive inventory of residual HCPs in your process intermediates and final drug substance.
GET A RELIABLE, COMPREHENSIVE INVENTORY OF RESIDUAL HCP IN YOUR PROCESS INTERMEDIATES AND FINAL DRUG SUBSTANCE
Why chose CellCarta for your Proteomic Assays
Mass spectrometry (MS) is the technology of choice for large-scale proteomic profiling and targeted quantitative biomarker analysis. CellCarta has led the way in the industrialization of MS platforms by applying them to the needs of the industry and refining MS workflows for specific clinical applications, all while applying GCLP principles and rigorous QA/QC.
